These results are part of a national study conducted by Veriheal, the healthcare company behind the nation’s largest medical marijuana use platform, in collaboration with US government scientists London School of Economics, University of Southern California and University of Maryland;; and the CREA (Cultivating Research Education and Advocacy) group, a business development and research company dedicated to psychoactive drugs such as cannabinoids, psychedelics, and entheogens. The results were formally presented to the American Chemical Society, a congressional chartered nonprofit research at the global chemical company April 2021 national conference.

Conducted between January 2020 and March 2021The study examined the interest and acceptance of medical cannabis for desired effects in terms of region, gender, and age group in relation to COVID-19 cases in America, as reported by the official COVID-19 CDC data tracker. The patient data comes from surveys on the Veriheal telemedicine platform, which connects potential cannabis patients with state-certified cannabis doctors to simplify and streamline the medical marijuana card (MMJ) application process.

The main results of the study show that:

  • 55% of medical cannabis users want to feel “happy” first and foremost. 29% feel relieved; 7% to feel “relaxed”; 5% feel sleepy
  • Happiness is the number one reason 39% of boomers use medicinal cannabis; 45% of gene X; 28% of Millennials and 29% of Gen Z.
  • Millennials are most likely to get a medical cannabis recommendation during COVID spikes, followed by Gen X and Gen Z.

“When we started investigating the relationship between medical cannabis use and COVID-19, our original hypothesis was that demand for cannabis with COVID-19 cases would increase as people seek physiological relief and ways to deal with stress “said Maha Haq, CEO of CREA and PhD student at University of Maryland School of Pharmacy. “We were amazed to find that the results actually nullify that hypothesis. Instead, we found that people seek psychological relief in response to exogenous shocks like COVID-19 and beyond. Periods of social unrest like the Black Lives protests Matter and the 2020 elections can be seen as a surge in medical cannabis interest in our datasets. “

In fact, data from the study, presented in the graph above, shows that registrations for medical cannabis consultations (dark blue) are of interest; and medical cannabis appointments (light blue) that represent adoption; Both rose along with the COVID-19 spikes in spring 2020 and spring 2021, protests against Black Lives Matter in summer 2020, presidential primaries in late summer, and the attempted coup in the U.S. Capitol in 2020 January 2021.

“Medical cannabis has traditionally been viewed as an alternative treatment for relieving physical pain and chronic ailments,” said Ms. Haq. “That most people actually look to the plant for the relief of psychological stressors, often related to external social upheaval, is an incredibly important discovery that is helping medical professionals better understand, and from there, the evolving relationship of consumers with cannabis improve the quality of their treatment related psychiatric programs. ”

The results of the study also provide insights into medical cannabis as a cultural phenomenon and support marketing initiatives over the past year that have increasingly focused on branding and differentiating cannabis based on its emotional impact rather than its physiological impact. The practice captures the attitudes of the new cannabis user and further prompts us to examine the evolving position of cannabis in the American cultural zeitgeist.

“It’s amazing to see Veriheal’s patient database being used to gain insight into the complexities of medical cannabis use in America,” he said Joshua Green, Co-Founder and CEO of Veriheal. “This is exactly the kind of application we dreamed of when we originally created our platform. Even more satisfying is that CREA and Maha Haq, a 2020 recipient of our Innovation in Cannabis Scholarship, have an essential role in making it a reality play this study. “

Veriheal announced one earlier this year $ 20,000 Innovation in cannabis scholarship to fund students pursuing a degree in the cannabis industry. The scholarship that was co-launched in 2020 $ 10,000 in awards, was doubled that year to offer 20 scholarships totaling $ 1,000 each to qualified student applicants.

Veriheal was founded by Samuel Adetunji and Joshua Green in 2017 with a mission to become the online destination for potential medical cannabis patients who wish to obtain an MMJ card and access educational resources. For one time $ 199 Veriheal streamlines and facilitates the end-to-end application process by connecting users with federally licensed doctors who can certify qualification requirements via telemedicine or in-person appointments – a requirement for all medical cannabis programs. Qualified patients receive a doctor’s recommendation and are assisted in applying for and obtaining their medical marijuana card.

Click here to view the full study.

About Veriheal
Veriheal is a health technology company dedicated to delivering personalized cannabis education and wellness to all people around the world. The Veriheal platform accomplishes this mission by connecting potential patients online with certified medical marijuana doctors to provide tailored medical recommendations to people seeking a better quality of life through cannabis. To learn more about the Veriheal platform, please visit

Media contact:
Alison Voetsch
[email protected]

SOURCE Veriheal